Literature DB >> 19005620

Oral cyclosporine A--the current picture of its liposomal and other delivery systems.

Aleksander Czogalla1.   

Abstract

The discovery of cyclosporine A was a milestone in organ transplantation and the treatment of autoimmune diseases. However, developing an efficient oral delivery system for this drug is complicated by its poor biopharmaceutical characteristics (low solubility and permeability) and the need to carefully monitor its levels in the blood. Current research is exploring various approaches, including those based on emulsions, microspheres, nanoparticles, and liposomes. Although progress has been made, none of the formulations is flawless. This review is a brief description of the main pharmaceutical systems and devices that have been described for the oral delivery of cyclosporine A in the context of the physicochemical properties of the drug and the character of its interactions with lipid membranes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005620      PMCID: PMC6275704          DOI: 10.2478/s11658-008-0041-6

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  73 in total

Review 1.  Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.

Authors:  Alfred Fahr; Peter van Hoogevest; Sylvio May; Nill Bergstrand; Mathew L S Leigh
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

2.  Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.

Authors:  Xue-qing Wang; Jia Huang; Jun-dong Dai; Tao Zhang; Wan-liang Lü; Hua Zhang; Xuan Zhang; Jian-cheng Wang; Qiang Zhang
Journal:  Int J Pharm       Date:  2006-05-16       Impact factor: 5.875

Review 3.  Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.

Authors:  Jagdish L Italia; Vivekanand Bhardwaj; M N V Ravi Kumar
Journal:  Drug Discov Today       Date:  2006-09       Impact factor: 7.851

4.  Interaction of cyclosporin A with dipalmitoylphosphatidylcholine.

Authors:  T S Wiedmann; T Trouard; S C Shekar; M Polikandritou; Y E Rahman
Journal:  Biochim Biophys Acta       Date:  1990-03-30

5.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  J M Kovarik; E A Mueller; J B van Bree; W Tetzloff; K Kutz
Journal:  J Pharm Sci       Date:  1994-03       Impact factor: 3.534

6.  Estimation of the increase in solubility of drugs as a function of bile salt concentration.

Authors:  S D Mithani; V Bakatselou; C N TenHoor; J B Dressman
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

7.  Cyclosporin A prodrugs: design, synthesis and biophysical properties.

Authors:  A R Hamel; F Hubler; A Carrupt; R M Wenger; M Mutter
Journal:  J Pept Res       Date:  2004-02

8.  The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome.

Authors:  C E Freise; T Liu; K Hong; R W Osorio; D Papahadjopoulos; L Ferrell; N L Ascher; J P Roberts
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

9.  Cyclosporin nanoparticulate lipospheres for oral administration.

Authors:  Tania Bekerman; Jacob Golenser; Abraham Domb
Journal:  J Pharm Sci       Date:  2004-05       Impact factor: 3.534

10.  Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics.

Authors:  A Fahr; M Holz; G Fricker
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

View more
  22 in total

1.  Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions.

Authors:  Syed Nazrin Ruhina Rahman; Oly Katari; Datta Maroti Pawde; Gopi Sumanth Bhaskar Boddeda; Abhinab Goswami; Srinivasa Rao Mutheneni; Tamilvanan Shunmugaperumal
Journal:  AAPS PharmSciTech       Date:  2021-05-13       Impact factor: 3.246

Review 2.  Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.

Authors:  Annette Bak; Dennis Leung; Stephanie E Barrett; Seth Forster; Ellen C Minnihan; Andrew W Leithead; James Cunningham; Nathalie Toussaint; Louis S Crocker
Journal:  AAPS J       Date:  2014-11-15       Impact factor: 4.009

3.  The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration.

Authors:  Alexandros Kourentas; Maria Vertzoni; Vicky Barmpatsalou; Patrick Augustijns; Stefania Beato; James Butler; Rene Holm; Neils Ouwerkerk; Joerg Rosenberg; Tomokazu Tajiri; Christer Tannergren; Mira Symillides; Christos Reppas
Journal:  AAPS J       Date:  2018-05-24       Impact factor: 4.009

Review 4.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 5.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

6.  The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies.

Authors:  Samar Hamdy; Azita Haddadi; Anooshirvan Shayeganpour; Aws Alshamsan; Hamidreza Montazeri Aliabadi; Afsaneh Lavasanifar
Journal:  AAPS J       Date:  2011-02-19       Impact factor: 4.009

Review 7.  Phospholipids and lipid-based formulations in oral drug delivery.

Authors:  Gert Fricker; Torsten Kromp; Armin Wendel; Alfred Blume; Jürgen Zirkel; Herbert Rebmann; Constanze Setzer; Ralf-Olaf Quinkert; Frank Martin; Christel Müller-Goymann
Journal:  Pharm Res       Date:  2010-04-22       Impact factor: 4.200

8.  Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.

Authors:  Ziyaur Rahman; Ahmed S Zidan; Muhammad J Habib; Mansoor A Khan
Journal:  Int J Pharm       Date:  2009-12-29       Impact factor: 5.875

9.  Analysis of Molecular Interactions between Components in Phospholipid-Immunosuppressant-Antioxidant Mixed Langmuir Films.

Authors:  Małgorzata Jurak; Klaudia Szafran; Pilar Cea; Santiago Martín
Journal:  Langmuir       Date:  2021-04-29       Impact factor: 3.882

10.  Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Authors:  Peipei Guan; Yi Lu; Jianping Qi; Mengmeng Niu; Ruyue Lian; Fuqiang Hu; Wei Wu
Journal:  Int J Nanomedicine       Date:  2011-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.